Tag: chairman

ARLINGTON, TX, June 03, 2026 (GLOBE NEWSWIRE) -- Greenway Technologies, Inc. (OTCQB: GWTI) (“Greenway”), an advanced gas-to-liquids (“GTL”) and gas-to-hydrogen (“GTH”) technology development company, announced that on May 28, 2026, Raymond Wright notified the Board of Directors (the “Board”) of Greenway of his resignation from his positions as a Board member and as Interim President of Greenway, effective on such date. In connection with his transition, the Board unanimously approved the conferral of the honorary title Chairman Emeritus in recognition of Mr. Wright’s long-standing leadership and foundational contributions to Greenway. The role of Chairman Emeritus is not a Board position and does not carry a vote.

TORONTO, June 03, 2026 (GLOBE NEWSWIRE) -- Kursat Kacira, the Chairman and CEO/President of Altai Resources Inc. (“Altai” or the “Company”), announced that he has disposed (the “Disposition”) of an aggregate of 11,100,000 common shares in the capital of the Company (the “Shares”). Prior to the Disposition, Mr. Kacira beneficially owned and controlled, directly and indirectly, an aggregate of 11,100,000 Shares, representing in aggregate approximately 19.8% of the total issued and outstanding Shares. After giving effect to the Disposition, Mr. Kacira does not beneficially own or control any securities in the capital of the Issuer.

Press release – Neuilly-sur-Seine, Wednesday June 3, 2026 – 5.45 pm

WASHINGTON, June 03, 2026 (GLOBE NEWSWIRE) --

WHAT:
The American Cornerstone Institute (ACI) will host the premiere of Star Spangled Adventures: The Movie!, a new family-friendly film designed to inspire patriotism, faith, and civic understanding in young Americans through storytelling and music.

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.